EA1131

Please Note: This trial is no longer enrolling new participants

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy

Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Mayer IA;Zhao F;Arteaga CL;Symmans WF;Park BH;Burnette BL;Tevaarwerk AJ;Garcia SF;Smith KL;Makower DF;Block M;Morley KA;Jani CR;Mescher C;Dewani SJ;Tawfik B;Flaum LE;Mayer EL;Sikov WM;Rodler ET;Wagner LI;DeMichele AM;Sparano JA;Wolff AC;Miller KD;
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131
Smith KL;Zhao F;Mayer IA;Tevaarwerk AJ;Garcia SF;Arteaga CL;Symmans WF;Park BH;Burnette BL;Makower DF;Block M;Morley KA;Jani CR;Mescher C;Dewani SJ;Brown-Glaberman U;Flaum LE;Mayer EL;Sikov WM;Rodler ET;DeMichele AM;Sparano JA;Wolff AC;Miller KD;Wagner LI;